Latest
Agilent cancer treatment approved in Europe
Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
